Exendin‑4 reverses endothelial dysfunction in mice fed a high‑cholesterol diet by a GTP cyclohydrolase‑1/tetrahydrobiopterin pathway
- Authors:
- Published online on: August 1, 2018 https://doi.org/10.3892/mmr.2018.9345
- Pages: 3350-3358
-
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
The vascular endothelium has an important function in maintaining homeostasis among a number of endothelial-derived factors including nitric oxide (NO), prostacyclin, endothelin-1 and angiotensin II. NO is now considered the most efficient endogenous vasodilator and it can exert vasoprotective effects by inhibiting platelet aggregation, inflammation, oxidative stress, fibrosis, vascular smooth muscle cell migration, proliferation, and leukocyte adhesion (1,2). However these functions of the endothelium can be weakened or eliminated by exposure to atherosclerosis risk factors. Endothelial dysfunction is a key factor in the initiation, progression and complications of atherosclerosis, and is now regarded as a clinical syndrome (3–5). Endothelial NO synthase (eNOS) is the key enzyme for NO generation. Tetrahydrobiopterin (THB) is a required cofactor for eNOS that is primarily regulated by its rate-limiting enzyme, guanosine triphosphate cyclohydrolase I (GCH1) (6,7).
Glucagon-like peptide-1 (GLP-1) is a potent glucose-dependent insulin tropic hormone that is released from intestinal L-cells. It has been observed that GLP-1 also has cardioprotective effects that are distinct from its glucose and weight-loss effects (8,9). The short half-life of GLP-1 and its effects on metabolites limit its clinical application (10).
Exendin-4 (Ex4; Food and Drug Administration approval number BYETTA; NDA; 021773; www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=021773), a GLP-1 analog, is a highly potent agonist of the GLP-1 receptor. As a result of its shared effects with GLP-1 and as it resists degradation by dipeptidyl peptidase 4, Ex4 has been approved by the United States Federal Drug Administration as an adjunct therapy to improve glycemic control in patients with type 2 diabetes mellitus.
Previous studies demonstrated that Ex4 has a protective effect against cardiovascular disease. For example, Ex4 exerts cardioprotective effects by improving endothelial function and acting as an antihypertensive, and these effects are independent of its hypoglycemic and weight-loss functions (11–13). d'Uscio et al (14) in 2016 demonstrated that exenatide treatment improved the coronary flow velocity reserve of patients with type 2 diabetes. Further study of human umbilical vein endothelial cells revealed that Ex4 increased NO production, GCH1 levels and eNOS activation via GLP-1R/cyclic adenosine monophosphate (cAMP) signaling pathways (15).
Apolipoprotein E knockout (APOE-KO) mice can develop severe hypercholesterolemia, atherosclerosis and associated endothelial dysfunction (14). Evidence has demonstrated that THB is involved in maintaining the normal function of eNOS (6,7), suggesting that THB and NOS may be associated. Phosphorylation of Ser1177 is associated with the activation of eNOS and enhances NO generation. Several studies have demonstrated that Ex4 improves endothelial function (16,17), but few studies have investigated the involvement of the GCH1/THB signaling pathway in endothelial dysfunction in mice fed a high-cholesterol diet (18).
It was hypothesized that Ex4 treatment may increase GCH1 and THB levels, thereby preserving normal eNOS function, to produce increased NO production (19,20,21). In the present study, the association between THB levels and eNOS function was examined. Furthermore, the effect of Ex4 on dysfunctional endothelium in the thoracic aorta isolated from APOE-KO mice given a high-cholesterol diet was investigated.
Materials and methods
All experiments were performed in accordance with protocols approved by the Guangxi Medical University Animal Ethics Committee (Nanning, China).
Animals
Genetically wild-type (WT) C57BL/6 mice (n=30; weight, 17.22±0.79 g) and APOE-KO mice of C57BL/6 background (n=30; weight, 20.12±0.96 g) were purchased from Charles River Laboratories, Inc., (Beijing, China). All of the mice were male and 6-weeks-old. The WT mice and the APOE-KO mice were each randomly and equally allocated to be treated either with Ex 4 (Ex4-treated) or not (controls). Therefore, 4 groups of 15 mice were created: i) WT control; ii) WT+Ex4; iii) APOE-KO control; and iv) APOE-KO+Ex4. The mice in the two treatment groups (WT+Ex4 and APOE-KO+Ex4) were intraperitoneally injected (IP) with Ex4 (1.0 nmol·kg−1·day−1, twice daily) for 8 weeks. The control groups were IP injected with an equal volume of physiological saline.
All the mice in all the groups were fed a high-cholesterol diet (1.25% cholesterol) starting at age 6 weeks and throughout the entire experiment. All mice were provided free access to food and water and atmosphere were maintained at a temperature of 23±2°C, 40–70% humidity and a 12-h light/dark-cycle.
Tissue procurement
This investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (22) and was approved by the Laboratory Animal Ethical Committee of Guangxi Medical University.
Following 8 weeks of treatment, the mice were anesthetized by pentobarbital (1%; 80 mg drug/kg animal body weight; IP) and euthanized by exsanguination. Blood samples were harvested from the heart (0.8–1 ml/mouse). The entire length of the aorta of each mouse was carefully dissected, from the aortic valve to the iliac bifurcation. The aorta was immediately put into a dish with ice-cold Krebs buffer (NaCl 120 mM, NaHCO3 25 mM, KCl 4.8 mM, NaH2PO4 1.2 mM, MgSO4 1.2 mM, dextrose 11.0 mM and CaCl2 1.8 mM aerated with 95% O2, pH=7.4). The fat and loose connective tissue was separated carefully under a light microscope and the gross specimen was observed.
The aorta was fixed in 10% formalin at room temperature of 25°C for 24 h and embedded in paraffin. Serial 5-µm sections were cut at the aortic arch and descending aorta and stained with hematoxylin/eosin (H&E) 1–3 min at room temperature for histological analysis. Aortas were frozen in liquid nitrogen for subsequent western blotting and high-performance liquid chromatography (HPLC), or prepared for the next vasomotor function experiment.
Pathology and morphological study
The aortic arch of each mouse was employed for the pathological and morphological study. The isolated arteries were observed under a dissecting microscope to study the gross appearance. Photographs of the gross specimen were captured with a NIKON camera (D5000; Nikon Corporation, Tokyo, Japan; Fig. 1). The arteries indicated in Fig. 1 were fixed with 4% paraformaldehyde for 24 h at room temperature and processed for paraffin embedding. Serial 4-µm transverse sections were taken at the aortic arch and stained with H&E for pathological study (Fig. 2) as described previously (23).
Plasma
The plasma glucose of each mouse was measured by the glucose oxidase method performed as described previously (24). (GOD-POD kit, Applygen Technologies Inc., Beijing, China). Insulin levels were monitored by radioimmunoassay as described previously (25) (Insulin RIA Kit, BNIBT, Beijing, China). Plasma triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were determined using an automated clinical biochemistry analyzer (Hitachi 7600; Hitachi, Ltd., Tokyo, Japan).
Artery endothelial function
Measurement of vascular relaxation
The descending thoracic aorta of each mouse was studied. The aorta was crosscut into 3–4 mm vascular rings, avoiding the intercostal artery branches and one side was mounted on a hook in an organ chamber containing 20 ml Krebs buffer (NaCl, 120 mM; NaHCO3, 25 mM; KCl, 4.8 mM; NaH2PO4, 1.2 mM; MgSO4, 1.2 mM; glucose, 11.1 mM; CaCl2, 1.8 mM, aerated with 95% O2 and 5% CO2, pH=7.4.) maintained at 37°C. The other side was connected with a force transducer to collect isometric tension data. The resting tension of the rings was increased gradually to 5 mN and equilibrated for 60 min. During equilibration, the Krebs buffer in the organ chamber was refreshed every 20 min.
Following equilibration, Krebs buffer with 60 mmol/l KCl was added into the chamber, 3 times, to determine the maximal depolarization-induced contractions. The rings were washed with Krebs buffer 3 times and re-equilibrated for 30 min.
Once vessels were pre-contracted at 37°C with L-phenylephrine (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany; 10−6 mol/l), the relaxation response to acetylcholine (10−5 mol/l; Sigma-Aldrich; Merck KGaA) was tested to confirm the integrity of the endothelium and then was equilibrated. The rings were pre-contracted with phenylephrine (1 M) and when they reached a stable contraction plateau, endothelium-dependent relaxation responses to cumulative concentrations of acetylcholine (10−9 to 10−5 mol/l) were measured.
Following another 3 washes with Krebs buffer and a 30 min equilibration, endothelium-independent relaxation responses to sodium nitroprusside (Sigma-Aldrich; Merck KGaA; 10−9 to 10−5 mol/l) were determined.
Western blot analysis
The snap-frozen aorta of each mouse was lysed with Radioimmunoprecipitation Assay buffer (Beyotime Institute of Biotechnology, Haimen, China) with 1 mmol/l fresh phenylmethylsulfonyl fluoride (Beyotime Institute of Biotechnology,) and a complete phosphatase inhibitor cocktail tablet ((Roche Diagnostics GmbH, Mannheim, Germany). The protein content was determined by a Bicinchoninic protein assay (Beyotime Institute of Biotechnology). Aorta protein extracts were denatured and 80 µg sample was loaded onto 10%SDS-PAGE gel and transferred. The resolved proteins in the gel were electro-transferred to a polyvinylidene fluoride membrane. The membrane was blocked with 5% (w/v) nonfat dry milk (dissolved in Tris-buffered saline with 0.05%Tween) for 1 h at room temperature.
Membranes were incubated serially overnight at 4°C with the following primary antibodies, diluted appropriately in primary antibody dilution buffer: Anti-eNOS (1:1,000; cat. no. sc654 Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-phosphorylated (p)-eNOS ser-1177 (1:1,000; cat. no. sc12972 Santa Cruz Biotechnology, Inc., Dallas, TX, USA); and anti-GCH1 (1:1,000; cat. no. ab236387 Abcam, Cambridge, UK).
The membranes were then washed in TBST 3 times for 10 min, incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:10,000; ZSGB-BIO; OriGene Technologies, Inc., Beijing, China.) for 1 h at room temperature and washed in TBST 3 times for 10 min. The immunoblots were visualized using a DAB chemiluminescence kit (Beyotime Institute of Biotechnology). Equal loading of protein was confirmed by blotting for GAPDH (1:1,000; cat. no. ta309157; ZSGB-BIO, Beijing, China). Protein levels were normalized with reference to GAPDH. p-eNOS ratios were normalized according to the total eNOS levels of corresponding groups. Relative band densitometry was analyzed by ImageJ software (ImageJ 1.44p; National Institutes of Health, Bethesda, MD, USA).
Measurement of THB and biopterin
Measurement of THB levels in aortas was performed using internal standard HPLC with florescence detection, as described previously (26). A total of three snap-frozen aortas from each group were lysed in ice-cold extraction buffer (50 mmol/l Tris-HCl, pH 7.4, 1 mmol/l dithiothreitol and 1 mmol/l EDTA), centrifuged at 13,000 × g for 10 min at 4°C and the supernatant was collected.
A protein assay was performed using a Bicinchoninic protein assay (Beyotime Institute of Biotechnology). The proteins from the supernatant were removed by adding 10 µl of a 1:1 mixture of 1.5 mol/l HClO4 and 2 mol/l H3PO4, to 90 µl extracts, and centrifuged at 13,000 × g for 10 min at 4°C. The supernatant was employed for THB measurement.
Total biopterin (THB, dihydropterin and biopterin) was determined by acidic oxidation using 10 µl of 1% iodine and 2% KI dissolved in 1 mol/l HCL, added to 90 µl protein-free supernatant. BH2+B was determined by alkaline oxidation. This was kept at room temperature in the dark for 1 h. A total of 20 µl, 1 mol/l H3PO4 was added to acidify the alkaline-oxidation samples. A total of 5 µl fresh ascorbic acid (20 mg/ml) was added into each sample to remove the iodine. Samples were centrifuged at 13,000 × g for 10 min at 4°C.
Biopterin (Sigma-Aldrich; Merck KGaA) was used for internal standard. A total of 20 µl of supernatant was loaded into a 250-mm long, 4.6-mm inner diameter Spherisorb ODS-1 column (Guangzhou Research and Creativity Biotechnology, Co., Ltd., Guangzhou, China) with a methanol-to-water (5:95, v/v) mobile phase running at a flow rate of 1.0 ml/min, column temperature was 25°C and detected fluorometrically at wavelengths of 350 nm for excitation and 440 nm for emission (LC-20 series, Shimadzu Corp., Kyoto, Japan).
Statistical analysis
In vitro experiments were repeated 3 times. Data are expressed as the mean ± standard deviation. One-way analysis of variance was used to examine the differences among the 4 groups of mice and the Student-Newman-Keuls post hoc test was used for a further pairwise comparison. All statistical analyses were performed using SPSS 16.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Plasma analyses and body weight of mice
Plasma TG, HDL-C, glucose and insulin levels were not significantly different among the 4 groups (Table I). The TC in the APOE-KO and APOE-KO+Ex4 groups was ~15-fold higher compared with the WT control and WT+Ex4 groups, and LDL-C levels were also significantly increased in the APOE-KO (P<0.01) and APOE-KO+Ex4 (P<0.01) groups. However, the TC and LDL-C levels were not statistically different between APOE-KO and APOE-KO+Ex4 groups.
There was a trend in the WT control group toward higher NO levels compared with the APOE-KO group, but the difference was not significant (Table I). However, NO levels in the APOE-KO+Ex4 mice were significantly increased to 37.3±12.6 µmol/l, which was nearly 2-fold higher compared with the APOE-KO group (20.0±7.4 µmol/l; P=0.015; both groups). The NO levels were also significantly 2-fold higher in the WT+Ex4 group (65.3±11.7 µmol/l) compared with the WT control group (27.1±7.4 µmol/l; P<0.001, both groups).
The body weights of mice were recorded and analyzed (Table II). The data regarding body weights demonstrated no significant difference between the APOE-KO and APOE-KO+Ex4 groups at 6- and 14-weeks-old. The body weights of the WT control and WT+Ex4 groups were also comparable at 6- and 14-weeks-old.
Histopathology and morphological changes of the arteries
Regarding general gross observation of the artery specimens, an atheromatous plaque was undetectable in the WT control (Fig. 1A) and WT+Ex4 (Fig. 1B) groups, and there was no vascular stenosis; they were normal in morphology. By contrast, in the untreated APOE-KO mice (Fig. 1C) specifically, the histopathology and morphological results demonstrated severe atherosclerosis of the aorta in the APOE-KO mice (Figs. 1 and 2). The arterial lumen was substantially stenosed by an atheromatous plaque, particularly at the aortic arch, the predilection site of arteriosclerotic lesions and also in certain principal branches. However, atherosclerosis was not grossly observed in the APOE-KO+Ex4 (Fig. 1D) group; the lumen and edge of the artery were clearly observed and appeared similar to that of the WT mice.
On microscopic examination of the sections stained with H&E, arteries of the WT control and WT+Ex4 (Fig. 2A and B) groups were similar in morphology. The intimae of the arteries were smooth, and the endothelia and muscle were arranged regularly. Atheromatous lesions could not be observed. Typical atheromatous lesions were demonstrated easily in the arteries of the APOE-KO (Fig. 2C) group, with a number of macrophages and foam cells in atheromatous plaques. The arterial wall was thickened homogeneously. In the APOE-KO+Ex4 (Fig. 2D) group, foam cells were also present in the subendothelium. Atherosclerotic lesions were not diffused so widely and thickening of the arterial wall was inconspicuous when compared with the APOE-KO group.
Endothelium-dependent vasodilation mediated by acetylcholine
Once arterial rings were pre-contracted with 10−6 mol/l phenylephrine, concentration-dependent acetylcholine-induced vasodilation was observed (Fig. 3). The maximum acetylcholine-induced-vasodilation of the arteries of the non-treated APOE-KO group (53.9±4.3%) was ~1.5 times that of the WT control group and was significantly different (77.9±8.7%; P<0.05; Fig. 3A). The maximum acetylcholine-induced-vasodilation of the arteries of the WT+Ex4 group was 98.9±2.1%, which was significantly higher compared with the WT control group (77.9±8.7%; P<0.05; both groups; Fig. 3B). By contrast, the maximum acetylcholine-induced-vasodilation in the APOE-KO+Ex4 mice was 87.8±3.6%, which was significantly increased compared with the APOE-KO group (53.9±4.3%; P<0.01; Fig. 3C). The 4 groups were comparable regarding the degree of sodium nitroprusside-induced endothelium-independent vasodilation (Fig. 3D).
eNOS and p-eNOS protein levels
Western blotting bands are presented in Fig. 4A. The results indicated that total eNOS protein levels in the arteries of the APOE-KO group were significantly increased compared the WT group (P=0.014). Ex4 treatment was associated with ~2-fold higher total eNOS protein levels in the APOE-KO+Ex4 group compared with the APOE-KO group (P<0.05). However, the total eNOS of the WT+Ex4 group was similar to that of the WT group (P=0.154; Fig. 4B).
The arterial p-eNOS protein levels were also investigated, and the WT control and APOE-KO groups were comparable. Ex4 treatment in the WT+Ex4 group was associated with a 3.5-fold increase in p-eNOS levels compared with the WT non-treated group (P<0.05) and with a 2-fold increase in the APOE-KO+Ex4 mice compared with the non-treated APOE-KO group (P<0.05; Fig. 4C)
GCH1 protein and THB levels
Western blotting analysis was employed to measure the vascular GCH1 protein level (Fig. 5A). GCH1 of the WT+Ex4 group were significantly higher when compared with the WT group (2.5-fold; P<0.05). The GCH1 level of the APOE-KO+Ex4 group were nearly 2-fold higher compared with the APOE-KO group (P=0.002; Fig. 5B).
Production of THB was detected by HPLC (Fig. 5C). The differences in arterial THB levels among the 4 groups were similar to the patterns observed in GCH1 protein and p-eNOS level. In the WT+Ex4 group, THB protein (1.34±0.03 pmol/mg), was significantly higher compared with the WT group (0.37±0.13 pmol/mg; P<0.05). THB protein of the APOE-KO+Ex4 group (0.75±0.14 pmol/mg) was 7-fold higher than that of the APOE-KO group (P<0.05). There was no difference in total biopterin among the 4 groups (Fig. 5C).
The ratio of BH4 to total biopterin was higher in the WT+Ex4 group (59.6±14.6%) when compared with the WT group (35.3±22%; P=0.065), although the difference was not significant. The ratio of BH4 to total biopterin in the APOE-KO+Ex4 group (34.3±9%) was significantly higher when compared with the APOE-KO group (5.4±2.3%; P=0.035; Fig. 5D).
Discussion
In this present study, it was demonstrated that a high-cholesterol diet was associated with higher TC and LDL-C in the APOE-KO mice compared with WT control mice. Also, the results of the present study demonstrated that Ex4 treatment was associated with improved endothelial dysfunction of the aortae in APOE-KO mice fed a high-cholesterol diet, without affecting blood lipid and glucose. The effect of Ex4 treatment was independent of TC, TG, LDL-C or glucose. A THB-suppressant was not used to demonstrate a link between THB and eNOS directly, since specific studies have investigated this previously (27,28). The acetylcholine-stimulated endothelium-dependent vasodilation was decreased in the APOE-KO mice when compared the WT control group. However, the condition of the aorta of the APOE-KO+ Ex4 group was improved. Similar improvement to the vascular condition was also observed in the WT+Ex4 mice compared with the non-treated WT control mice.
Similar to the results of the present study, a previous study demonstrated that Ex4 treatment directly elicited significant and concentration-dependent vasorelaxation in the rat aortas (29). Ozyazgan et al (29) used Ex4 for the long-term treatment of type 2 diabetic rats and demonstrated that Ex4 treatment returned the acetylcholine-induced relaxation response to approximately that of the control group, which is similar to the results of the present study. Different results of endothelial dysfunction of rat arteries demonstrated neither a direct protective effect on endothelial dysfunction nor vasorelaxation effects of Ex4 (30). However, this may be explained by the endothelial protective effect of Ex4 is due to multi-factors in vivo rather than rapidly in vitro.
In the present study, it was demonstrated that the NO levels in the APOE-KO mice were lower when compared with the WT control mice. This indicated that the production of NO was reduced, or its half-life had been shortened. By contrast, in the Ex4 intervention groups the plasma NO level was higher by 2-fold (WT+Ex4) and 1.5-fold (APOE-KO+Ex4) compared with non-treated groups. The mechanism may involve cAMP/5′-AMP-activated protein kinase-Associated signaling pathways and enhancement of eNOS activity (16). It is hypothesized that the positive effect on endothelial function of Ex4 may involve eNOS.
Acetylcholine-stimulated endothelium-dependent vasodilation was impaired in APOE-KO mice; it was significantly lower than that of the WT control group. However, the aorta condition of the APOE-KO+Ex4 group was better and their arteries performed well in acetylcholine-induced endothelium-dependent vasodilation. Similar improvement of vascular condition was also observed in the WT+Ex4 mice compared with the non-treated WT control mice. A previous isolated vessel study on standard rats demonstrated that Ex4 treatment directly elicited significant and concentration-dependent vasorelaxation in rat aortas (31). However the maximal relaxation only reached ~30%. This may be associated with the healthy animal model. the scale of the improvement seems less significant compare with APOE-KO mice which were suffering more severe endothelial injury.
Kuhlencordt et al (32) observed the atherosclerotic lesion area of ApoE/eNOS-double knockout mice and demonstrated that atherosclerosis was more severe in eNOS-deficient mice compared with the APOE-KO mice. This may indicate that eNOS has a protective cardiovascular effect. Notably, in the study by Ozaki et al (28), the atherosclerotic lesion areas of the aorta were unexpectedly increased in APOE-KO/eNOS-transgene (Tg) mice (eNOS-overexpressing) compared with APOE-KO mice. A previous study demonstrated that endothelial cells incubated with exenatide can increase eNOS protein levels but did not increase the expression of eNOS mRNA (33). This may indicate that Ex-4 regulates eNOS expression without affecting eNOS gene transcription. It is hypothesized that Ex4 treatment led to a more normalized eNOS function in the APOE-KO+Ex4 group relative to the non-treated APOE-KO mice.
It was established that the phosphorylation of eNOS on serine 1,177 can activate the enzyme and lead to NO production (34,35). The present study demonstrated that p-eNOS levels were increased in mice treated with Ex4, for the APOE-KO and WT control mice, and the treated groups exhibited higher plasma NO. These results suggested that Ex4 may have a protective effect towards eNOS activity. This is similar to previous in vitro studies, which suggests that Ex4 upregulated p-eNOS in human umbilical vein endothelial cells and human coronary artery endothelial cells (17,19,33).
THB, a cofactor of NOS regulates eNOS activity (20,36). And GCH1 is the first and rate-limiting enzyme for THB de novo synthetic pathway (21), so THB is mainly determined by the content and bioactivity of GCH1. The results of the present study demonstrated that vascular GCH1 and THB protein levels were decreased in the APOE-KO group compared with the WT control group. Cai et al (20) demonstrated that GCH1 gene transfer in endothelial cells notably increased THB, enhanced eNOS homodimerization and increased NO production, suggesting that GCH1 may be a reasonable target to augment endothelial THB and normalize eNOS activity in endothelial dysfunction. The present study hypothesized that the severe abnormal function and uncoupling of eNOS in APOE-KO mice was due in part to the absence of THB, and ultimately led to a lower NO level.
Hattori et al (37) treated APOE-KO mice with oral THB and observed that continuous THB availability improved NO-mediated endothelial function and limited the progression of atherosclerosis. In the present study, it was also demonstrated that arterial GCH1 protein level were increased in the APOE-KO+Ex4 (~2-fold) and the WT+Ex4 (2.5-fold) groups, compared with their respective non-treated groups.
The THB content of the 2 intervention groups were correspondingly higher and the increase in the APOE-KO+Ex4 group was ~7-fold compared with the non-treated APOE-KO mice. Similar to previous studies, Bendall et al (38) demonstrated that eNOS protein was significantly increased in the eNOS-Tg and eNOS/GCH1-transgene mice. However, the ratio of eNOS dimer-to-monomer was significantly decreased in eNOS-Tg mice and its superoxide production was significantly increased. By contrast, with sufficient THB levels of superoxide the function of eNOS was normal in eNOS/GCH-Tg mice. Takaya et al (39) reported that atherosclerotic lesion formation was increased in APOE-KO/eNOS-Tg mice compared with APOE-KO mice, while atherosclerotic lesions were reduced in APOE-KO/eNOS-Tg/GCH-Tg mice, which had higher vascular THB compared with APOE-KO/eNOS-Tg mice. The present study demonstrated a similar phenomenon.
Apart from the GCH1-THB-eNOS signaling pathway, one of the important mechanisms of Ex4 on cardiovascular protection, previous studies have demonstrated that Ex4 can improve myocardial function in heart failure by reversing cardiac remodeling (40–42). Evidence from a previous study indicated that Ex4 reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages and may contribute to the attenuation of atherosclerotic lesions (43). This effect may also help preserve the bioactivity of THB and eNOS, and is good for endothelial function and cardiovascular disease.
Although the sample size of the present study was small, the statistical power in this study remain valid. Also, the present study, to the best of our knowledge, is the first study using the flow-mediated dilation technique to suggest that long-term administration of Ex4 improves arterial dilation.
In conclusion, models of endothelial dysfunction in APOE-KO mice were established and the results provide strong evidence that systemic application of Ex4 can reverse endothelial dysfunction in APOE-KO mice induced by a high-cholesterol diet. The present study also suggested that the protective mechanisms associated with Ex4 treatment may primarily concern the promotion of GCH1 expression and increase of THB level. Furthermore, adequate THB may help maintain normal eNOS function and preserve eNOS phosphorylation to improve endothelial function and achieve cardiovascular protection.
Acknowledgements
Authors would like to thank Qiaoyun Tang (Life Science Institute of Guangxi Medical University) for the excellent technical support.
Funding
The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81260059).
Availability of data and materials
All data generated or analyzed during the present study are included in this published article.
Authors' contributions
ZT, LL, YG, GD and MC performed experiments. LL provided animal experiment technical assistance. ZT analyzed and interpreted data. ZT drafted the manuscript. ZT, YG and JW edited and revised manuscript. JW and ZT contributed to conception and design of research. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All experiments were performed in accordance with protocols approved by the Guangxi Medical University Animal Ethics Committee (Nanning, China).
Patient consent for publication
Not applicable.
Competing interests
The authors declare they have no competing interests.
References
|
Zhou X, Chen X, Cai JJ, Chen LZ, Gong YS, Wang LX, Gao Z, Zhang HQ, Huang WJ and Zhou H: Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway. Drug Des Devel Ther. 9:4599–4611. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Vanhoutte PM and Leung SW: Vascular nitric oxide: Beyond eNOS. J Pharmacol Sci. 129:83–94. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Park KH and Park WJ: Endothelial dysfunction: Clinical implications in cardiovascular disease and therapeutic approaches. J Korean Med Sci. 30:1213–1225. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bonetti PO, Lerman LO and Lerman A: Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 23:168–175. 2002. View Article : Google Scholar | |
|
Husain K, Hernandez W, Ansari RA and Ferder L: Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem. 6:209–217. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Alkaitis MS and Crabtree MJ: Recoupling the cardiac nitric oxide synthases: Tetrahydrobiopterin synthesis and recycling. Curr Heart Fail Rep. 9:200–210. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fukai T: Endothelial GTPCH in eNOS uncoupling and atherosclerosis. Arterioscler Thromb Vasc Biol. 27:1493–1495. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ and Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 117:2340–2350. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ussher JR and Drucker DJ: Cardiovascular biology of the incretin system. Endocr Rev. 33:187–215. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nadkarni P, Chepurny OG and Holz GG: Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci. 121:23–65. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chiquette E, Toth PP, Ramirez G, Cobble M and Chilton R: Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag. 8:621–629. 2012.PubMed/NCBI | |
|
Simo R, Guerci B, Schernthaner G, Gallwitz B, Rosas-Guzman J, Dotta F, Festa A, Zhou M and Kiljanski J: Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: Results from the European exenatide study. Cardiovasc Diabetol. 14:1162015. View Article : Google Scholar : PubMed/NCBI | |
|
Seufert J and Gallwitz B: The extra-pancreatic effects of GLP-1 receptor agonists a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab. 16:673–688. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
d'Uscio LV, Baker TA, Mantilla CB, Smith L, Weiler D, Sieck GC and Katusic ZS: Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 21:1017–1022. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Wei R, Ma S, Wang C, Ke J, Yang J, Li W, Liu Y, Hou W, Feng X, Wang G and Hong T: Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab. 310:E947–E57. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Han L, Yu Y, Sun X and Wang B: Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res Clin Pract. 97:453–460. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Erdogdu O, Eriksson L, Xu H, Sjoholm A, Zhang Q and Nystrom T: Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol. 50:229–241. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Alp NJ, McAteer MA, Khoo J, Choudhury RP and Channon KM: Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase i overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 24:445–450. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Erdogdu O, Nathanson D, Sjoholm A, Nystrom T and Zhang Q: Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 325:26–35. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cai S, Alp NJ, McDonald D, Smith I, Kay J, Canevari L, Heales S and Channon KM: GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc Res. 55:838–849. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Moens AL and Kass DA: Tetrahydrobiopterin and Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 26:2439–2444. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
National Research Council: Guide for the Care and Use of laboratory animals. Washington, DC: The National Academies Press; 1996 | |
|
Fischer AH, Jacobson KA, Rose J and Zeller R: Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2008:2008. | |
|
Burrin JM and Price CP: Performance of three enzymic methods for filter paper glucose determination. Ann Clin Biochem. 21:411–416. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Jones PM, Salmon DM and Howell SL: Protein phosphorylation in electrically permeabilized islets of Langerhans. Efects of Ca2+, cyclic AMP, a phorbol ester and noradrenaline. Biochem J. 254:397–403. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Fukushima T and Nixon JC: Analysis of reduced forms of biopterin in biological tissues and fluids. Anal Biochem. 102:176–188. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Alp NJ, McAteer MA, Khoo J, Choudhury RP and Channon KM: Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 24:445–450. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ozaki M, Kawashima S, Yamashita T, Hirase T, Namiki M, Inoue N, Hirata K-i, Yasui H, Sakurai H, Yoshida Y, et al: Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest. 110:331–340. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Ozyazgan S, Kutluata N, Afsar S, Ozdas SB and Akkan AG: Effect of glucagon-like peptide-1(7–36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology. 74:119–126. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nathanson D, Erdogdu O, Pernow J, Zhang Q and Nystrom T: Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept. 157:8–13. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS and Grieve DJ: GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys. 478:136–142. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH and Huang PL: Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation. 104:448–454. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ding L and Zhang J: Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin. 33:75–81. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Michell BJ, Griffiths JE and Mitchelhill KI: The Akt kinase signals directly to endothelial nitric oxide. Current Biology. 9:845–848. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Matsumoto S, Shimabukuro M, Fukuda D, Soeki T, Yamakawa K, Masuzaki H and Sata M: Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser1177/Thr497 of endothelial nitric oxide synthase in diabetic mice. Cardiovascular Diabetology. 13:1–10. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Du YH, Guan YY, Alp NJ, Channon KM and Chen AF: Endothelium-Specific GTP Cyclohydrolase I Overexpression Attenuates Blood Pressure Progression in Salt-Sensitive Low-Renin Hypertension. Circulation. 117:1045–1054. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hattori Y, Hattori S, Wang X, Satoh H, Nakanishi N and Kasai K: Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 27:865–870. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, Yokoyama M, Kawashima S and Channon KM: Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: Insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res. 97:864–871. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Takaya T, Hirata K, Yamashita T, Shinohara M, Sasaki N, Inoue N, Yada T, Goto M, Fukatsu A, Hayashi T, et al: A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression. Arterioscler Thromb Vasc Biol. 27:1632–1637. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lorber D: GLP-1 receptor agonists: Effects on cardiovascular risk reduction. Cardiovasc Ther. 31:238–249. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Okerson T and Chilton RJ: The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 30:e146–155. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Monji A, Mitsui T, Bando YK, Aoyama M, Shigeta T and Murohara T: Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol. 305:H295–H304. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R and Watada H: Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 59:1030–1037. 2010. View Article : Google Scholar : PubMed/NCBI |
